Michael A. Postow, MD

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the results of the COMBI-AD study and the CheckMate-238 study will impact the care of patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targets beyond PD-1 in melanoma.

Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.

Postow says there have been algorithms developed over recently years to determine patient's toxicities and prescribe certain immunosupressive treatments to help abate the symptoms.

Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.

Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses sequencing strategies in treating patients with melanoma.